| Name | Title | Contact Details |
|---|---|---|
Kim Barratt |
Chief Talent Officer | Profile |
VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.
Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Breas was founded in 1991 in Gothenburg, Sweden and has become one of the global leaders in Home Mechanical Ventilation, Airway Clearance and Sleep therapy.
We believe that empowering movement within healthcare environments is essential to quality care. ⚖️ https://t.co/e11hfbUA49
Genvion Corporation is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.